Geometry.Net - Health_Conditions: Hyperlipidemia

Hyperlipidemia / Hypercholesterolemia: MediFocus MedCenter Preview
hyperlipidemia/Hypercholesterolemia (CR008) Introduction Other relatedterms used are high cholesterol, hyperlipidemia, and dyslipidemia.
http://www.eoutletcenter.com/medcenter/CR008.HTM

Extractions: Cholesterol (also called lipid) is a fat-like substance that deposits in the walls of blood vessels. It can contribute to the development of heart disease in certain individuals. Hypercholesterolemia is the clinical term for high levels of cholesterol in the blood. Other related terms used are high cholesterol, hyperlipidemia, and dyslipidemia. While cholesterol is the most commonly referred-to element of the lipid profile, there are several elements that are tested, with differing significance of elevated or low levels. The desirable levels of the different elements vary somewhat depending on the presence of other risk factors of coronary artery disease (CAD).
MediFocus MedCenter Preview For Hyperlipidemia/Hypercholesterolemia
MediFocus MedCenter © hyperlipidemia/Hypercholesterolemia (CR008). Other relatedterms used are high cholesterol, hyperlipidemia, and dyslipidemia.
http://www.slmseniors.com/medguides/cr008.htm

Extractions: Hyperlipidemia/Hypercholesterolemia Cholesterol (also called lipid) is a fat-like substance that deposits in the walls of blood vessels. It can contribute to the development of heart disease in certain individuals. Hypercholesterolemia is the clinical term for high levels of cholesterol in the blood. Other related terms used are high cholesterol, hyperlipidemia, and dyslipidemia. While cholesterol is the most commonly referred-to element of the lipid profile, there are several elements that are tested, with differing significance of elevated or low levels. The desirable levels of the different elements vary somewhat depending on the presence of other risk factors of coronary artery disease (CAD). Hyperlipidemia is known to be a key factor in the development of atherosclerosis (plaques that cause blockage of blood vessels) and is the greatest risk factor for the development of CAD. In the U.S., 500,000 men and women die of CAD each year. High cholesterol is not always due to dietary intake of saturated foods. There are also hereditary disorders of cholesterol over-production and deposition. This is called familial hypercholesterolemia and can be difficult to treat.
CRI Registry - Hyperlipidemia Investigators
hyperlipidemia INVESTIGATORS. Select a state and city, select aclinic / research center and review the information presented
http://www.criregistry.com/Hyperlipidemia.htm
CVS ProCare - Transplant Clinical Resource | Transplantation And Hyperlipidemia
Transplant Clinical Resource Transplantation and hyperlipidemiaWhat Is It and Why Should I be Concerned?
http://www.stadtlander.com/content/transplant/clinical/tx_hyperlipidemia.html

Extractions: Prepared By Keven J. Lynch, PharmD, BCPS Over the past few years, multiple immunosuppressant agents have become available. This means that the transplant physician is now able to tailor the transplant recipient's medication regimen according to his or her unique characteristics or other ongoing illnesses. One of the reasons for customizing transplant medication regimens is the risk of some long-term complications related to the immunosuppressive agents. We've all heard the concerns about gaining too much weight and eating too much cholesterol. This is especially concerning for transplant recipients since the long-term complications that can occur include post-transplant obesity and hyperlipidemia. Hyperlipidemia, or increased cholesterol and/or triglycerides in the blood, over time, can lead to cardiovascular disease. Heart disease is the primary cause of death in stable organ transplant recipients. In other words, organ preservation, surgical technique, post-operative care and the immunosuppressants available today are improving the life of the transplanted organ. But, recipients are primarily succumbing to cardiovascular illness.
Nutrition - "Intervention For Hyperlipidemia Associated With Protease Inhibitors
www.HIVdent.org. Nutrition News Update Intervention for hyperlipidemiaAssociated With Protease Inhibitors . Intervention for hyperlipidemia
http://www.hivdent.org/nutrifhawpi0799.htm

Extractions: Journal of the Association of Nurses in AIDS Care (07/99-08/99) Vol. 10, No. 4, P. 55; Melroe, N. Holly; Kopaczewski, Jessica; Henry, Keith; et al. Recent studies have indicated that protease inhibitors may raise lipids to levels that pose an extremely serious health risk. Researchers conducted a study to determine whether interventions outlined by the National Cholesterol Education Program (NCEP) Guidelines would be effective in reducing protease inhibitor-related hyperlipidemia. The study involved 45 HIV-infected individuals taking protease inhibitors, with abnormally high lipid levels. Interventions consisted of diet, exercise, the prescription drug gemfribozil alone or with atorvatstatin. During a 10-month period of intervention, the mean cholesterol level of participants dropped to 201 mg/dl, a substantial decline. Because the study cohort was small, investigators recommend further research. In addition, they note that more aggressive use of lipid lowering agents was used than that specified by the NCEP.
Club C@reNet [club Hyperlipidemia] INDEX
The summary for this Japanese page contains characters that cannot be correctly displayed in this language/character set.
http://club.carenet.co.jp/Hyperlipidemia/index.asp?SID=
AEGiS-AIDS Weekly: AIDS Therapies: Protease Inhibitor-Induced Hyperlipidemia Cau
Click here to return to AIDS WEEKLY PLUS main menu AIDS Therapies ProteaseInhibitorInduced hyperlipidemia Caused by Increased Production
http://www.aegis.com/pubs/aidswkly/2001/AW010206.html

Extractions: Michael Greer, Staff Medical Writer NewsRx Biologists in the United States have presented evidence implicating the liver in the excessive lipid levels induced by commonly used treatments for HIV infection. "Hyperlipidemia may complicate the use of HIV protease inhibitors (PIs) in AIDS therapy," J.M. Lenhard and colleagues at Glaxo Wellcome explained in the journal Arteriosclerosis Thrombosis and Vascular Biology The researchers examined the etiology of PI-induced hyperlipidemia both in vitro and in vivo, using HepG2 liver cells and a murine model involving AKR/J mice ("HIV protease inhibitors stimulate hepatic triglyceride synthesis," Arterioscler Thromb Vasc Biol 2000 Dec;20(12):2625-9 Exposing the hepatic cells to a number of PIs, including nelfinavir, ritonavir, and saquinavir, resulted in a marked stimulation of triglyceride output, the researchers found. Ritonavir administration also resulted in an increase in cholesterol synthesis by HepG2 cells, study data showed, while nelfinavir exposure induced an upregulation of fatty acid synthase and diacylglycerol acyltransferase mRNA. However, neither amprenavir or indinavir produced any measurable effect in this model. The murine model revealed possible variations in the metabolic effects of nelfinavir and ritonavir. Both PIs had similar effects on fed mice, increasing triglyceride and fatty acid levels while having no effect on cholesterol and blood glucose, according to the report. However, Lenhard et al. found that ritonavir induced pronounced elevations in triglyceride, cholesterol, and blood sugar levels in fasting mice, while nelfinavir had no effect. Administration of either PI with the triglyceride clearance inhibitor Triton WR-1339 doubled or tripled triglyceride levels in these mice, the researchers noted.
Hyperlipidemia: Side Effects And Patient Ratings For Prescription Drugs
Consumer ratings reports for the hyperlipidemia drug class. The followingdrug reviews are available for the class hyperlipidemia.
http://www.askapatient.com/classreport.asp?class=HYPERLIPIDEMIA
[Press Release] Cholesterol Lowering Treatments Continue To Challenge Hyperlipid
hyperlipidemia medication noncompliance can have severe and costly clinical consequences,as well as measurable effects in terms of direct and indirect costs.
http://www.the-infoshop.com/press/ww12400_en.shtml

Extractions: Home Contact about The Infoshop Catalog ... Devices / Components Press Release Hyperlipidemia medication noncompliance can have severe and costly clinical consequences, as well as measurable effects in terms of direct and indirect costs. Also, underutilization of cholesterol lowering medications result in significant product revenue loss for pharmaceutical manufacturers. More importantly, lowering blood cholesterol levels can reduce the short-term risk for heart attack by 40%. The rate of compliance with hyperlipidemia treatments is low, causing an estimated 125,000 deaths per year. This Hyperlipidemia Patient Compliance report provides important insights into specific treatment compliance issues underlying hyperlipidemia, a lipid disorder also known as hypercholesterolemia or "high cholesterol." Despite the availability of numerous pharmaceuticals for the treatment of hyperlipidemia, significant obstacles to patients' compliance with these therapies, as well as dietary and exercise regimens, remain. The preventative, rather than curative nature of hyperlipidemia treatment is one such challenge. Numerous additional factors result in differing rates of compliance among patients. Patients report reasons for delay and/or omitted drug doses, as well as not following dietary and exercise regimens. Hyperlipidemia Patient Compliance is a newly released report from EP Publications, a service of WWMR, providing compliance rates, factors influencing compliance, strategies for improving compliance, and the resulting implications for the pharmaceutical industry. Key findings from patient interviews - including direct quotes, critical desires of patients in terms of compliance, reasons for non-compliance - are also included in the report.
Hyperlipidemia
hyperlipidemia This is a newborn mini donkey and her mother at a zoowhere I used to work. What is hyperlipidemia and what causes it?
http://pages.ivillage.com/annalar16/hyperlipidemia.html

Extractions: This is a newborn mini donkey and her mother at a zoo where I used to work. The mother is way too fat for a donkey. The big neck is all fat deposits. This picture is typical of the types of donkeys that are most likely to be affected by hyperlipidemia. Momma got put on a diet to help her health out. Hyperlipidemia is a disease that affects very fat donkeys, mules and ponies. Horses can also be affected, but not as often. The prognosis for this disease is not very good. Usually, more that 60% of animals affected, will not live. The purpose for this page is to help donkeys owners learn more about this problem and to be aware of the signs and treatment of this disease so that you can pass this information on to your vets. Many vets are not aware of this problem in donkeys. What is Hyperlipidemia and what causes it? Hyperlipidemia is a condition in which there is an elevated level of lipids(fat) in the blood stream. This includes both triglycerides and cholesterol being elevated. Hyperlipidemia can be caused by a genetic defect that affects fat metabolism. However, many cases of hyperlipidemia are actually secondary results of a different disease like diabetes or cushings disease. Obesity combined with stress of some type is one of the major factors leading to the hyperlipidemia. Other factors include hormonal imbalances, or losing weight to rapidly. Because of this sudden weight loss, or stress, the body hormones mistakenly think that the donkey is starving and causes the release of large amounts of fat that have been stored in the body cells. Due to the large amounts of fat in the blood stream, the brain also releases another hormone that shuts off the animals appetite.
NMAP: The UK's Gateway To High Quality Internet Resources In Nursing, Midwifery,
hyperlipidemia up. hyperlipidemia / diagnosis hyperlipidemia / diagnosis.AACE medical guidelines for clinical practice for the
http://nmap.ac.uk/browse/mesh/detail/C0020473L0020473.html

Extractions: British Hyperlipidaemia Association The aim of the British Hyperlipidaemia Association (BHA) is to "foster scientific research and good clinical practice related to the management of hyperlipidaemia in the UK." The Web site provides information about the BHA, its activities and events, committee members, and access to a selection of related advice sheets. The BHA incorporates the Family Heart Association. Academies and Institutes Great Britain Hyperlipidemia Societies, Medical AACE medical guidelines for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis This document, prepared by clinical endocrinologist members of the American Association of Clinical Endocrinologists, is designed to review the "current understanding of the diagnosis of dyslipidemia and provide a guideline for the treatment of lipid disorders and the relationship of these disorders to atherogenesis." Case studies are presented throughout the document, and there are special sections that address the cardiovascular dysmetabolic syndrome, dyslipidemia of diabetes, dyslipidemia in pediatric patients, PCOS, estrogen theory, cost-to-benefit considerations, and non-lipid associated risk factors. The document was ammended in 2002. It is PDF which requires the Adobe Acrobat Reader.
HyperlipidemiaA PDR® Clinical Handbook
hyperlipidemiaA PDR® Clinical Handbook hyperlipidemiaA PDR Clinical Handbookprovides guidelines that afford maximal benefit to patients at acceptable
http://www.medec.com/html/products/productdetail/hyperlip.html

Extractions: Areas covered within include: Adherence to the guidelines by both patients and providers is key to approximating the magnitude of the benefits demonstrated in clinical trials. You will find recommendations for the use of state of the art multidisciplinary methods targeting the patient, providers, and health delivery systems to achieve the full effectiveness of the guidelines for primary and secondary prevention.
Hyperlipidemia
hyperlipidemia, defined as total blood cholesterol levels 240 mg/dL,has not been directly associated with an increased risk for stroke.
http://www.umassmed.edu/strokestop/module_two/hyperlipidemia.html

Extractions: Hyperlipidemia, defined as total blood cholesterol levels 240 mg/dL, has not been directly associated with an increased risk for stroke. This is different from coronary artery disease, where the relationships are clear and well understood. However recent trials show reduced stroke risk after total cholesterol reduction.
Positional Cloning Of The Combined Hyperlipidemia Gene Hyplip1
1 pp 110 116 Positional cloning of the combined hyperlipidemia gene Hyplip1 JackieS. Bodnar 1 , Aurobindo Chatterjee 2 , Lawrence W. Castellani 1 , David A
http://www.nature.com/cgi-taf/DynaPage.taf?file=/ng/journal/v30/n1/abs/ng811.htm
Familial Combined Hyperlipidemia
Familial combined hyperlipidemia. Definition Alternative Names Multiplelipoproteintype hyperlipidemia. Causes, incidence, and risk factors
http://www.pennhealth.com/ency/article/000396.htm

Extractions: Causes, incidence, and risk factors: This disease is genetic and is inherited in an autosomal dominant manner but the specific defective gene(s) have not been identified. Elevations in the cholesterol and/or triglyceride levels appear during the teenage years and continue throughout life. Types of elevated lipoproteins may vary between affected family members. Cholesterol deposits in the skin, called xanthomas, that are seen in other disorders of elevated lipoproteins are rarely seen in this disorder. This disorder predisposes the person to increased risk of early coronary artery disease and therefore, heart attacks. The incidence of obesity and glucose intolerance is increased. The condition is worsened by
Hyperlipidemia : Meddie Health Search
ITEMS LINKS Familial Combined hyperlipidemia Overview Adam.com givesa definition, the causes, incidence and risk factor of this disease.
http://www.meddie.com/search/Health/Conditions_and_Diseases/Nutrition_and_Metabo
INCIDENCE OF HYPERLIPIDEMIA IN KIDNEY TRANSPLANT PATIENTS TREATED WITH A COMBINA
646. INCIDENCE OF hyperlipidemia IN KIDNEY TRANSPLANT PATIENTS TREATED WITH ACOMBINATION REGIMEN OF SIROLIMUS(RAPA)CYCLOSPORINE(CSA)-PREDNISONE(PRED).
http://www.a-s-t.org/abstracts99/646.htm

Extractions: Introduction: There has been concern about the effect of Rapa to potentiate hyperlipidemia, a condition that undoubtedly contributes to the high cardiovascular morbidity in renal transplant recipients. This study sought to assess the incidence and evolution of hyperlipidemia among a clinical cohort under treatment with Rapa-CsA-Pred. Materials: 83 renal transplant recipients received Rapa-CsA-Pred regimen de novo from November 1993 to February 1998.The database included demographic factors, concomitant medications, as well as serial measurements of fasting serum triglyceride and cholesterol levels, serum creatinine, urine protein excretion, and liver function tests. Results: Demographic data of the overall cohort showed a mean patient age of 41.5 years, a male-to-female ratio of 1.5, and 32% incidence of diabetes. Time (months) Pre n= Cholesterol 240mg/dl (%) Triglyceride 400mg/dl(%) Cholesterol:(mean) mg/dl Triglyceride(median) mg/dl Conclusion: Hyperlipidemia showed an onset at one month, peak at 3 months and stabilization thereafter with countermeasure therapy, although, persistently remaining greater than pretransplant values.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

81-97 of 97 Back | 1 | 2 | 3 | 4 | 5